Evergreen Capital Management LLC Has $349,000 Stock Holdings in Glaukos Co. (NYSE:GKOS)

Evergreen Capital Management LLC raised its stake in Glaukos Co. (NYSE:GKOS) by 26.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,945 shares of the medical instruments supplier’s stock after purchasing an additional 623 shares during the period. Evergreen Capital Management LLC’s holdings in Glaukos were worth $349,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 486 shares in the last quarter. Caldwell Sutter Capital Inc. increased its position in Glaukos by 5,860.0% during the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after acquiring an additional 1,465 shares during the period. Fifth Third Wealth Advisors LLC bought a new position in Glaukos during the second quarter worth about $187,000. Brighton Jones LLC acquired a new stake in Glaukos in the 2nd quarter worth about $208,000. Finally, Mount Yale Investment Advisors LLC bought a new stake in Glaukos in the 2nd quarter valued at about $212,000. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Performance

Glaukos stock opened at $127.48 on Friday. The stock has a market cap of $6.42 billion, a PE ratio of -44.26 and a beta of 1.03. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $136.60. The business’s 50-day moving average price is $125.24 and its two-hundred day moving average price is $112.48.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $88.86 million. During the same period in the prior year, the company earned ($0.55) EPS. The firm’s quarterly revenue was up 19.0% compared to the same quarter last year. As a group, analysts expect that Glaukos Co. will post -2.18 earnings per share for the current fiscal year.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 2,250 shares of the company’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $121.39, for a total value of $273,127.50. Following the completion of the transaction, the chief operating officer now owns 101,845 shares of the company’s stock, valued at approximately $12,362,964.55. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, COO Joseph E. Gilliam sold 2,250 shares of Glaukos stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $121.39, for a total transaction of $273,127.50. Following the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at $12,362,964.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,500 shares of company stock worth $5,099,000. Insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

GKOS has been the topic of several recent research reports. Piper Sandler raised their target price on shares of Glaukos from $110.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Morgan Stanley lifted their price objective on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Stifel Nicolaus increased their target price on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Citigroup cut Glaukos from a “buy” rating to a “neutral” rating and raised their price target for the stock from $130.00 to $132.00 in a research report on Wednesday, July 10th. Finally, StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $129.82.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.